Abstract
Head and neck cancers remain a significant health problem globally. The addition of chemotherapy to radiotherapy for locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) has led to improvements in locoregional disease control and in survival, but is associated with substantial acute and late toxicities. In recurrent and/or metastatic SCCHN, there have been no improvements in survival, despite the manipulation of standard therapeutic regimens and the introduction of newer cytotoxic agents. Over the last decade, targeted therapies have been increasingly used in a range of solid tumor types. This article discusses the clinical evidence for the use of a number of targeted agents in the treatment of locoregionally advanced and recurrent and/or metastatic SCCHN. The article focuses on the epidermal growth factor receptor (EGFR) inhibitors, for which the majority of clinical information is available. These include the monoclonal antibody (MAb) cetuximab and the tyrosine kinase inhibitors, erlotinib and gefitinib. Clinical data for the vascular endothelial growth factor (VEGF) inhibitor, bevacizumab, are also presented.
Keywords: Cetuximab, bevacizumab, EGFR, head and neck cancer, panitumumab, targeted therapies
Reviews on Recent Clinical Trials
Title: Targeted Therapies in Head and Neck Cancer: Past, Present and Future
Volume: 3 Issue: 3
Author(s): Alexander D. Rapidis, Jan B. Vermorken and Jean Bourhis
Affiliation:
Keywords: Cetuximab, bevacizumab, EGFR, head and neck cancer, panitumumab, targeted therapies
Abstract: Head and neck cancers remain a significant health problem globally. The addition of chemotherapy to radiotherapy for locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) has led to improvements in locoregional disease control and in survival, but is associated with substantial acute and late toxicities. In recurrent and/or metastatic SCCHN, there have been no improvements in survival, despite the manipulation of standard therapeutic regimens and the introduction of newer cytotoxic agents. Over the last decade, targeted therapies have been increasingly used in a range of solid tumor types. This article discusses the clinical evidence for the use of a number of targeted agents in the treatment of locoregionally advanced and recurrent and/or metastatic SCCHN. The article focuses on the epidermal growth factor receptor (EGFR) inhibitors, for which the majority of clinical information is available. These include the monoclonal antibody (MAb) cetuximab and the tyrosine kinase inhibitors, erlotinib and gefitinib. Clinical data for the vascular endothelial growth factor (VEGF) inhibitor, bevacizumab, are also presented.
Export Options
About this article
Cite this article as:
Rapidis D. Alexander, Vermorken B. Jan and Bourhis Jean, Targeted Therapies in Head and Neck Cancer: Past, Present and Future, Reviews on Recent Clinical Trials 2008; 3 (3) . https://dx.doi.org/10.2174/157488708785700285
DOI https://dx.doi.org/10.2174/157488708785700285 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic issue: Discovering New Anticancer Activities from Old Drugs)
Current Medicinal Chemistry Anti-Egfr Therapy in Colorectal Cancer: How to Choose The Right Patient
Current Drug Targets Anticancer Peptides and Proteins: A Panoramic View
Protein & Peptide Letters Molecular Probes for Malignant Melanoma Imaging
Current Pharmaceutical Biotechnology Protein Kinase C Isozymes as Potential Targets for Anticancer Therapy
Current Cancer Drug Targets Macromolecular Drug Targets in Cancer Treatment and Thiosemicarbazides as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Killing Glioma ‘Stem-like’ Cells via Drug-Induced Relocation of Endosomal Urokinase Proteins
Anti-Cancer Agents in Medicinal Chemistry Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors
Current Pharmaceutical Design Based on Nucleotides Analysis of Tumor Cell Lines to Construct and Validate a Prediction Model of Mechanisms of Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Aurora Kinase Inhibitors in Head and Neck Cancer
Current Topics in Medicinal Chemistry Better Targeting Melanoma: Options Beyond Surgery and Conventional Chemotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Nitroimidazole Radiopharmaceuticals in Hypoxia: Part II Cytotoxicity and Radiosensitization Applications
Current Radiopharmaceuticals Subungueal Haemorrhages Following Docetaxel (Taxotere) Treatment
Current Drug Safety Using Cytokines to Treat Cervical Intraepithelial and Invasive Neoplasia
Recent Patents on Anti-Cancer Drug Discovery Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness
Current Stem Cell Research & Therapy Polymeric Nanoparticles of FMISO: Are Nano-Radiopharmaceuticals Better Than Conventional Ones?
Current Radiopharmaceuticals Targeting the Fibroblast Growth Factor Receptors for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Surfactant Protein A - From Genes to Human Lung Diseases
Current Medicinal Chemistry Development of Cisplatin Nanoparticles as Dry Powder Inhalers for Lung Cancer
Current Nanoscience Copper-62 Labeled ReCCMSH Peptide Analogs for Melanoma PET Imaging
Current Radiopharmaceuticals